ClinicalTrials.gg
Active, not recruitingNCT04553133Updated May 6, 2026

PF-07104091 as a Single Agent and in Combination Therapy

A Phase 2 interventional study of PF-07104091 monotherapy dose escalation and PF-07104091 + palbociclib + fulvestrant in Small Cell Lung Cancer, Ovarian Cancer and Breast Cancer, sponsored by Pfizer. Active, not recruiting at 22 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
157
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Small Cell Lung Carcinoma by Pfizer — 4 open to participants now, 5 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Pfizer.

Enrollment
8th of 12
157 · median 227
Started
2020
with 1 other
Phase 2
4 of 12
1 open now
Registered
9th of 12
by date

Among the 12 studies in Small Cell Lung Carcinoma by Pfizer, this one is the 8th largest by enrollment, is one of 2 that started in 2020, is one of 4 in phase 2, and was the 9th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

4 of the 12 studies in Small Cell Lung Carcinoma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Small Cell Lung Carcinoma by Pfizer, or all of them as a file.
02

Study summary

To assess the safety and tolerability of increasing doses of PF-07104091 and to estimate the Maximum Tolerated Dose (MTD) and/or select the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with advanced or metastatic small cell lung, breast and ovarian cancers.

Read the detailed description

Study C4161001 is a Phase 1, open label, multi dose, multi center, dose escalation, safety, pharmacokinetic (PK) and pharmacodynamic study of PF-07104091 in adult patients with advanced or metastatic small cell lung cancer (SCLC), advanced platinum resistant epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer, locally recurrent/advanced or metastatic triple negative breast cancer (TNBC), HR-positive HER2-negative advanced or mBC, advanced or metastatic non-small cell lung cancer (NSCLC). This two part study will assess the safety and tolerability of increasing dose levels of PF-07104091 in Part 1, and establish the recommended Phase 2 dose (RP2D) in Part 2.

03

Conditions studied

  • Small Cell Lung Cancer
  • Ovarian Cancer
  • Breast Cancer

Keywords

  • Hormone receptor-positive human epidermal growth factor receptor 2 negative breast cancer
  • Cyclin-Dependent Kinase 2 Inhibitor
  • PF-07104091
  • palbociclib
  • letrozole
  • cyclin-dependent kinase
  • Ibrance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with HR-positive -negative advanced or breast cancer (received at least two prior lines in the advanced or metastatic setting including one prior line of combined CDK4/6 inhibitor and endocrine therapy and no more than two prior lines of cytotoxic chemotherapy)
  • Participants with locally recurrent/advanced or metastatic TNBC who have received up to 2 in the advanced or metastatic setting
  • Participants with advanced platinum resistant epithelial ovarian cancer (EOC)/fallopian tube cancer/primary peritoneal cancer (PPC) ( or cytologically proven) who have received at least 1 systemic anti-cancer therapy containing a platinum analog
  • Participants with cytological diagnosis of advanced/metastatic SCLC
  • Participants with or cytological diagnosis of advanced/metastatic NSCLC
  • Participants with HR-positive HER2-negative advanced or metastatic breast cancer (second line plus setting) (histologically or cytologically proven).
  • Participants entering the study in the expansion cohort have at least one as defined by version 1.1 that has not been previously irradiated
  • Performance Status 0 or 1
  • Adequate bone marrow, hematological, kidney and liver function
  • Resolved acute effects of any prior therapy to baseline severity

Exclusion criteria

Exclusion Criteria:

  • Participants with known symptomatic requiring
  • Participants with any other active within 3 years prior to enrollment
  • Major surgery within 3 weeks prior to study entry
  • Radiation therapy within 3 weeks prior to study entry.
  • Systemic anti cancer therapy within 4 weeks prior to study
  • Prior irradiation to >25% of the bone marrow
  • Participants with active, uncontrolled bacterial, fungal, or viral infection, including , , and known or AIDS related illness
  • Active COVID-19/SARS-CoV2 infection
  • Baseline 12 lead that demonstrates abnormalities that may affect participant safety or interpretation of study results
  • Any of the following in the previous 6 months: myocardial infarction, long syndrome, Torsade de Pointes, arrhythmias, serious conduction system abnormalities, unstable angina, coronary/peripheral artery bypass graft, symptomatic CHF, class III or IV, cerebrovascular accident, , symptomatic pulmonary embolism, and/or other clinical significant episode of thrombo embolic disease.
  • Anticoagulation with vitamin K antagonists or factor Xa inhibitors is not allowed.
  • Hypertension that cannot be controlled by medications
  • Participation in other studies involving drug(s) within 2 weeks prior to study entry.
  • Known or suspected to active ingredient/ in PF 07104091.
  • Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
  • Participants with advanced/, symptomatic, visceral spread, that are at risk of life threatening complications in the short
  • Participants with an indwelling catheter that has an external component such as those used for drainage of effusion(s) or central venous catheter that is externally
  • Previous high dose chemotherapy requiring stem cell rescue
  • Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding intramuscular injections of goserelin (if applicable).
  • Current use or anticipated need for food or drugs that are known strong /5 or UGT1A9 inhibitors or inducers
  • Current use or anticipated need for drugs that are known sensitive UGT1A1 substrates with narrow therapeutic
  • Serum pregnancy test positive at screening
  • Other medical or psychiatric condition
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    PF-07104091

    CDK2 monotherapy dose escalation

    Drug: PF-07104091 monotherapy dose escalation

  • Experimental
    PF-07104091 + palbociclib + fulvestrant

    CDK2 + palbociclib + fulvestrant

    Drug: PF-07104091 + palbociclib + fulvestrant

  • Experimental
    PF-07104091 + palbociclib + letrozole

    CDK2 + palbociclib + letrozole

    Drug: PF-07104091 + palbociclib + letrozole

  • Experimental
    PF-07104091 monotherapy dose expansion (SCLC)

    PF-07104091 monotherapy dose expansion (SCLC)

    Drug: PF-07104091 monotherapy dose expansion (SCLC)

  • Experimental
    PF-07104091 monotherapy dose expansion (ovarian)

    PF-07104091 monotherapy dose expansion (ovarian)

    Drug: PF-07104091 monotherapy dose expansion (ovarian)

  • Experimental
    PF-07104091 + fulvestrant (post CDK4/6) dose expansion

    PF-07104091 + fulvestrant (post CDK4/6) dose expansion

    Drug: PF-0704091 + Fulvestrant (post CDK4/6)

  • Experimental
    PF-07104091 + fulvestrant (post CDK 4/6) dose escalation

    CDK2+ fulvestrant (post CDK 4/6) dose escalation

    Drug: PF-07104091 + Fulvestrant (post CDK4/6)

Interventions

  • DrugPF-07104091 monotherapy dose escalation

    PF-07104091 will be administered orally

  • DrugPF-07104091 + palbociclib + fulvestrant

    Drug pages: Palbociclib · Fulvestrant

    PF-07104091 will be administered orally in combination with palbociclib and fulvestrant

  • DrugPF-07104091 + palbociclib + letrozole

    Drug pages: Palbociclib · Letrozole

    PF-07104091 will be administered orally in combination with palbociclib and letrozole

  • DrugPF-07104091 monotherapy dose expansion (ovarian)

    PF-07104091 will be administered orally

  • DrugPF-07104091 monotherapy dose expansion (SCLC)

    PF-07104091 will be administered orally

  • DrugPF-07104091 + Fulvestrant (post CDK4/6)

    Drug page: Fulvestrant

    PF-07104091 will be administered orally in combination with fulvestrant

  • DrugPF-0704091 + Fulvestrant (post CDK4/6)

    Drug page: Fulvestrant

    PF-07104091 + fulvestrant (post 4/6) dose expansion

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle

    Number of participants with DLTs, which are typically Grade 3 or higher adverse events will be summarized by dose level

    Time frame: 28 days

  2. To evaluate incidence of treatment emergent adverse events and laboratory abnormalities

    Type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events and any laboratory abnormalities will be summarized by dose level

    Time frame: From baseline until end of study treatment or study completion (approximately 2 years)

  3. Evaluate pulse rate that is out of normal range and changes in pulse rate as compared to baseline

    Identify pulse rate readings that are outside the normal range. The number and percentage of participants who experienced significant pulse rate change from baseline will be summarized by dose level

    Time frame: From baseline until end of study treatment or study completion (approximately 2 years)

  4. Evaluate blood pressure that is out of normal range and changes in blood pressure as compared to baseline

    Identify systolic and diastolic readings that are outside the normal range. The number and percentage of participants who experienced significant blood pressure change from baseline will be summarized by dose level

    Time frame: From baseline until end of study treatment or study completion (approximately 2 years)

  5. To evaluate heart rate corrected QT interval and changes in corrected QT interval as compared to baseline

    Determine the effect of the drug on QT prolongation. The number and percentage of participants who experienced QT interval prolongation will be summarized by dose level

    Time frame: From baseline until end of study treatment or study completion (approximately 2 years)

  6. To evaluate the preliminary antitumor activity of PF-07104091 as a single agent and in combination with palbociclib and in combination with letrozole or fulvestrant or fulvestrant alone by objective response rate (ORR) in dose expansion

    Percentage of participants with a best overall response of complete response (CR) or partial response (PR) using RECIST 1.1

    Time frame: From baseline through disease progression or study completion (approximately 2 years)

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of PF-07104091 after a single dose and multiple dose

    Peak concentration of PF-07104091 during selected cycles

    Time frame: Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)

  2. Time to maximum plasma concentration (Tmax) of PF-07104091 after a single dose and multiple dose

    Time to peak concentration of PF-07104091 during selected cycles

    Time frame: Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)

  3. Area under the concentration versus time curve from time zero to the last quantifiable time point prior to the next dose (AUClast) of PF-07104091

    AUC of PF-07104091 will be calculated at selected cycles

    Time frame: Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)

  4. Area under the curve of PF-07104091 with or without food

    AUC of PF-07104091 in plasma and whether absorption of the drug is affected when taken by food

    Time frame: From baseline through time to event on study or study completion (approximately 2 years)

  5. Maximum plasma concentration of PF-07104091 with or without food

    Peak concentrations of PF-07104091 in plasma and whether absorption of the drug is affected when taken by food

    Time frame: From baseline through time to event on study or study completion (approximately 2 years)

  6. To document any preliminary evidence of antitumor activity of PF-07104091 as a single agent and in combination with palbociclib and in combination with letrozole or fulvestrant or fulvestrant alone by objective response rate (ORR) in dose escalation

    Percentage of participants with a best overall response of CR or PR using RECIST 1.1

    Time frame: From baseline and every 8 weeks through disease progression or study completion (approximately 2 years)

  7. To document any preliminary evidence of antitumor activity of PF-07104091 by time to event endpoints

    Time from first assessment of event endpoint to last assessment of using RECIST 1.1

    Time frame: From baseline through time to event on study or study completion (approximately 2 years)

07

Study locations

22 sites
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Dec 2026, 75 months after the start.

Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's planned 75 months is above that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2020
First posted
Sep 17, 2020
StartActual
Sep 16, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04553133
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 17, 2020
Start date
Sep 16, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 6, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Palbociclib · Fulvestrant · Letrozole

Start the discussion